JP2013507394A - 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 - Google Patents

自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 Download PDF

Info

Publication number
JP2013507394A
JP2013507394A JP2012533364A JP2012533364A JP2013507394A JP 2013507394 A JP2013507394 A JP 2013507394A JP 2012533364 A JP2012533364 A JP 2012533364A JP 2012533364 A JP2012533364 A JP 2012533364A JP 2013507394 A JP2013507394 A JP 2013507394A
Authority
JP
Japan
Prior art keywords
lactobacillus
composition
pediococcus
pharmaceutically acceptable
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012533364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507394A5 (cg-RX-API-DMAC10.html
Inventor
スティーブン エフ オルムステッド
Original Assignee
プロセラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロセラ インコーポレイテッド filed Critical プロセラ インコーポレイテッド
Publication of JP2013507394A publication Critical patent/JP2013507394A/ja
Publication of JP2013507394A5 publication Critical patent/JP2013507394A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2012533364A 2009-10-09 2010-10-08 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 Pending JP2013507394A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25022009P 2009-10-09 2009-10-09
US61/250,220 2009-10-09
PCT/US2010/052076 WO2011044516A2 (en) 2009-10-09 2010-10-08 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015255700A Division JP2016084352A (ja) 2009-10-09 2015-12-28 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法

Publications (2)

Publication Number Publication Date
JP2013507394A true JP2013507394A (ja) 2013-03-04
JP2013507394A5 JP2013507394A5 (cg-RX-API-DMAC10.html) 2013-11-28

Family

ID=43857421

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012533364A Pending JP2013507394A (ja) 2009-10-09 2010-10-08 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
JP2015255700A Pending JP2016084352A (ja) 2009-10-09 2015-12-28 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
JP2017195604A Pending JP2018027972A (ja) 2009-10-09 2017-10-06 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015255700A Pending JP2016084352A (ja) 2009-10-09 2015-12-28 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
JP2017195604A Pending JP2018027972A (ja) 2009-10-09 2017-10-06 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法

Country Status (5)

Country Link
US (1) US20110091431A1 (cg-RX-API-DMAC10.html)
EP (2) EP2485744A4 (cg-RX-API-DMAC10.html)
JP (3) JP2013507394A (cg-RX-API-DMAC10.html)
CA (1) CA2774963A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011044516A2 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020067368A1 (ja) * 2018-09-26 2020-04-02 株式会社明治 ミトコンドリア機能改善剤
JP2021100946A (ja) * 2015-05-22 2021-07-08 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 自閉症スペクトラム障害および関連する症候を治療するための方法
JP2023549205A (ja) * 2020-11-12 2023-11-22 シンバイオティクス アクティエボラーグ 共生組成物
JP2024507187A (ja) * 2021-02-10 2024-02-16 中科微智（北京）生物科技有限公司 ビフィドバクテリウム・ラクティス及びその使用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG66608B1 (bg) * 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN114949001A (zh) 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
US20170105647A1 (en) * 2014-05-15 2017-04-20 Children's Medical Center Corporation Systems and methods for identifying neurobiological biomarkers using eeg
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR20170086492A (ko) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
HUE062788T2 (hu) 2016-04-15 2023-12-28 Baylor College Medicine Lactobacillus reuteri MM4-1A alkalmazása az autizmus spektrumzavar kezelésében vagy megelõzésében
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
WO2018053308A1 (en) 2016-09-15 2018-03-22 Sun Genomics Llc Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
KR20190127710A (ko) * 2017-02-07 2019-11-13 캘리포니아 인스티튜트 오브 테크놀로지 헌팅톤병 및 레트 증후군에서의 장 미생물총의 조정
CN111787933A (zh) * 2017-03-28 2020-10-16 森永乳业株式会社 阿片肽分解用组合物
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
US20210128567A1 (en) * 2017-08-29 2021-05-06 Flaask, Llc Compositions and Methods for Cognitive, Immune and Digestive Support in Patients with Autism Spectrum Disorder
WO2019075456A2 (en) 2017-10-13 2019-04-18 Locus Ip Company, Llc METHODS AND SUBSTANCES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES
KR102218992B1 (ko) 2017-12-12 2021-02-23 한국생명공학연구원 아가토바쿨룸 속 균주를 유효성분으로 함유하는 자폐 범주성 장애의 예방, 개선 또는 치료용 조성물
EP3768287A2 (en) * 2018-03-22 2021-01-27 Adare Pharmaceuticals SAS New use of microbiological compositions
CN109172615A (zh) * 2018-09-07 2019-01-11 北京金锋实验室科技有限公司 用于治疗自闭症患者的益生菌
WO2020087046A1 (en) * 2018-10-26 2020-04-30 Sun Genomics Inc. Universal method for extracting nucleic acid molecules from a diverse population of microbes
WO2020154712A1 (en) * 2019-01-25 2020-07-30 Flaask, Llc Compositions and methods for improving quality of life in patients with autism spectrum disorder
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
JP6739602B1 (ja) * 2019-07-24 2020-08-12 雪印メグミルク株式会社 記憶・学習能維持および／または向上用組成物及び組成物を含む食品、医薬品、飼料
CA3161418C (en) * 2019-12-17 2024-05-21 Noelle Marie PATNO Multi-strain probiotic composition and its use
JP2023511275A (ja) * 2020-01-13 2023-03-17 サイオート バイオサイエンシーズ， インコーポレイテッド 自閉症および関連障害を処置または改善するための方法
CN115052969A (zh) * 2020-02-06 2022-09-13 李旺祚 用于预防或治疗雷特氏综合征的乳酸菌组合物
TWI770463B (zh) * 2020-02-06 2022-07-11 國立臺灣大學 用於預防或治療雷特氏症的乳酸菌組成物
RU2733713C1 (ru) * 2020-02-11 2020-10-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ прогнозирования эффективности коррекции поведенческих расстройств у детей с аутизмом при соблюдении безглютеновой диеты
WO2021161205A1 (en) * 2020-02-13 2021-08-19 Eyal Research Consultants Ltd Microbial combinations with modulators of the opioid system and uses thereof
CN111455076B (zh) * 2020-04-17 2022-10-21 济南市儿童医院 用于儿童孤独症评估的口腔菌群微生物
CA3199346A1 (en) * 2020-12-09 2022-06-16 Nebojsa Janjic Methods and compounds for treatment of autism spectrum disorder
CN113018318A (zh) * 2021-01-19 2021-06-25 北京科拓恒通生物技术股份有限公司 乳双歧杆菌Probio-M8及其制品用于制备治疗ASD药物的用途
CN112852670B (zh) * 2021-01-26 2022-08-09 青岛东海药业有限公司 一种婴儿双歧杆菌dh231及其发酵产物、应用和微生态制剂
CN115919907A (zh) * 2021-08-31 2023-04-07 E·施约林 一种用于治疗和/或预防食物和/或酒精中毒的组合物
CN117918526B (zh) * 2023-12-01 2026-04-17 山东省大健康精准医疗产业技术研究院 一种孤独症谱系障碍改善剂及其制备方法与应用
CN117431190B (zh) * 2023-12-14 2024-03-12 深圳未知君生物科技有限公司 一株能够缓解自闭症谱系障碍的短双歧杆菌及其应用
EP4670726A1 (en) * 2024-06-28 2025-12-31 N.V. Nutricia COMPOSITION TO IMPROVE INTESTINAL HEALTH ASSOCIATED WITH A STATE OF THE INTESTINAL-BRAIN AXIS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20070286916A1 (en) * 2004-02-17 2007-12-13 Synbiotics Ab Synbiotic Use

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716615A (en) * 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
EP0574681A1 (en) * 1992-06-15 1993-12-22 Quest International B.V. Yogurt product containing bacteriocin from pediococcus adilactici
AUPM823094A0 (en) * 1994-09-16 1994-10-13 Goodman Fielder Limited Probiotic compositions
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
IT1288119B1 (it) * 1996-06-28 1998-09-10 Renata Maria Anna Ve Cavaliere Composizioni dietetiche da utilizzare nell'alimentazione per via enterica
CN1254256A (zh) * 1997-03-24 2000-05-24 维微亚美国交易股份有限公司 稳定的固体细菌组合物
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
SI0931543T1 (en) * 1997-12-19 2002-10-31 Merck Patent Gmbh Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
EP1034788A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
RO121700B1 (ro) * 1999-03-11 2008-02-28 Societe Des Produits Nestle S.A. Bacterii lactobacillus capabile să prevină diareea cauzată de bacterii patogene şi rotavirusuri
US6468525B1 (en) 1999-08-10 2002-10-22 Renew Life, Inc. Probiotic formulation
US6251391B1 (en) * 1999-10-01 2001-06-26 Klaire Laboratories, Inc. Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons
US6447772B1 (en) 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
US6271983B1 (en) * 1999-11-05 2001-08-07 Storage Technology Corporation Rotary access port for automated tape library
US6613549B2 (en) * 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
ATE419331T1 (de) * 2000-08-25 2009-01-15 Wakamoto Pharma Co Ltd L. salivarius-stamm enthaltende probiotische produkte
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
US6808810B2 (en) * 2000-12-20 2004-10-26 Sumitomo Chemical Company, Limited Resin composition, laminate and production of laminate
US20040204469A1 (en) * 2001-06-19 2004-10-14 Norbert Muller Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
ITMI20020399A1 (it) 2002-02-28 2003-08-28 Ct Sperimentale Del Latte S P Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
US6585996B1 (en) * 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
PL212647B1 (pl) * 2002-03-21 2012-11-30 Bifodan As Kompozycja farmaceutyczna, szczep Lactobacillus paracasei Lbp PB01 oraz szczep Lactobacillus paracasei Lbp PB01 w polaczeniu ze szczepem Lactobacillus acidophilus Lba EB01, produkt chlonny zawierajacy te kompozycje oraz produkt nabialowy, produkt nutraceutyczny i czynnosciowy produkt zywnosciowy zawierajace ten szczep albo te dwa szczepy, a takze zastosowanie tego szczepu albo tych dwóch szczepów
US20050101520A1 (en) * 2002-03-29 2005-05-12 Harumi Jyonouchi CTLA4 compositions in the treatment of autism
US20040092589A1 (en) * 2002-06-21 2004-05-13 Liisa Neumann Use of retinoic acid for treatment of autism
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
ATE477811T1 (de) * 2002-10-03 2010-09-15 Neuropharmacology Services Llc Oxytocin zur behandlung von autismus und asperger-syndrom
US7179460B2 (en) * 2002-12-05 2007-02-20 Danisco A/S Bacterial composition and its use
US7122370B2 (en) * 2003-01-14 2006-10-17 Randolph Stanley Porubcan Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life
US20060233777A1 (en) 2003-04-01 2006-10-19 Andrea Piva Use of bacteriocin for the amelioration of digestive functionality
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
EP1624762B1 (en) 2003-05-22 2007-02-28 Synbiotics AB A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and a fiber fermenting property
US20060165661A1 (en) 2003-06-13 2006-07-27 N>V> Nutricia Pediocin-producing pediococci
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US8871266B2 (en) * 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
CN101001635A (zh) * 2003-12-04 2007-07-18 生物膜策略公司 预防生物膜形成、减少现有生物膜和减少细菌群的方法和组合物
US20050130288A1 (en) 2003-12-11 2005-06-16 Eromlife Co., Ltd. Novel microorganism Pediococcus pentosaceus EROM101, having immune enhancement, anticancer and antimicrobial activities
US7252957B2 (en) * 2004-02-03 2007-08-07 Immunosciences Lab., Inc. Identification of etiology of autism
US20050186188A1 (en) 2004-02-19 2005-08-25 Peilin Guo Compositions containing probiotics and polysaccharides and methods of use
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20050276806A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
AU2005257033B2 (en) * 2004-06-23 2011-05-12 L'oreal Method and compositions useful for preventing and/or treating sensitive and/or dry skin
US7935334B2 (en) 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
US20060008511A1 (en) * 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
US20060020037A1 (en) * 2004-07-22 2006-01-26 Allergan, Inc. Tazarotenic acid and esters thereof for treating autism
MX2007004135A (es) * 2004-10-04 2007-06-15 Oreal Composicion cosmetica y/o dermatologica para pieles sensibles.
US20060269508A1 (en) * 2005-03-29 2006-11-30 Trejo Amy V Means for regulating the cosmetic appearance and/or health of human keratinous tissue
EP2308566B1 (en) * 2005-04-08 2017-07-05 The Procter and Gamble Company Use of orally administered probiotic bifidobacteria for human beauty benefits
US20070092501A1 (en) * 2005-04-26 2007-04-26 Prothera, Inc. Compositions and methods relating to reduction of symptoms of autism
WO2007081981A2 (en) * 2006-01-11 2007-07-19 Attune Foods Probiotic food, process for its preparation and dietary regimen
US20070191440A1 (en) * 2006-01-25 2007-08-16 Solomon Michael E Methods of treating autism and fragile X syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20070286916A1 (en) * 2004-02-17 2007-12-13 Synbiotics Ab Synbiotic Use

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021100946A (ja) * 2015-05-22 2021-07-08 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 自閉症スペクトラム障害および関連する症候を治療するための方法
JP7273082B2 (ja) 2015-05-22 2023-05-12 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 自閉症スペクトラム障害および関連する症候を治療するための方法
WO2020067368A1 (ja) * 2018-09-26 2020-04-02 株式会社明治 ミトコンドリア機能改善剤
JPWO2020067368A1 (ja) * 2018-09-26 2021-08-30 株式会社明治 ミトコンドリア機能改善剤
JP7498455B2 (ja) 2018-09-26 2024-06-12 株式会社明治 ミトコンドリア機能改善剤
US12083152B2 (en) 2018-09-26 2024-09-10 Meiji Co., Ltd. Agent for improving mitochondrial function
JP2023549205A (ja) * 2020-11-12 2023-11-22 シンバイオティクス アクティエボラーグ 共生組成物
JP2024507187A (ja) * 2021-02-10 2024-02-16 中科微智（北京）生物科技有限公司 ビフィドバクテリウム・ラクティス及びその使用
JP7687725B2 (ja) 2021-02-10 2025-06-03 中科微智（北京）生物科技有限公司 ビフィドバクテリウム・ラクティス及びその使用
US12559714B2 (en) 2021-02-10 2026-02-24 Wisbiom (Beijing) Biotechnology Co., Ltd. Bifidobacterium animalis subsp. lactis and use thereof

Also Published As

Publication number Publication date
CA2774963A1 (en) 2011-04-14
JP2018027972A (ja) 2018-02-22
EP2485744A2 (en) 2012-08-15
EP3260126A1 (en) 2017-12-27
JP2016084352A (ja) 2016-05-19
US20110091431A1 (en) 2011-04-21
EP2485744A4 (en) 2014-01-22
WO2011044516A3 (en) 2011-09-22
WO2011044516A2 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
JP2018027972A (ja) 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
Dudek-Wicher et al. Clinical trials of probiotic strains in selected disease entities
Varankovich et al. Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases
CN113180109B (zh) 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
CA2837479C (en) Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US11752179B2 (en) Medical use of probiotics
Foligné et al. Probiotic properties of non-conventional lactic acid bacteria: immunomodulation by Oenococcus oeni
Jeronymo-Ceneviva et al. Probiotic properties of lactic acid bacteria isolated from water-buffalo mozzarella cheese
US20200121740A1 (en) Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
KR102794442B1 (ko) 신규한 프로바이오틱스 비피도박테리움 균주
Contaldo Use of probiotics for oral candidiasis: state of the art and perspective. A further step toward personalized medicine?
WO2018181069A1 (ja) オピオイドペプチド分解用組成物
Mohamed Probiotics benefits, potential limitations and risks
EP2734057B1 (en) Probiotic formulation
Mikawlrawng et al. Drug interactions, safety and efficacy of probiotics
US20230310519A1 (en) Use of adlercreutzia bacteria for the treatment of inflammatory diseases
Patra et al. Determination and safety aspects of probiotic cultures
Stavropoulou et al. Functions of the human intestinal microbiota in relation to functional foods
Arora et al. Emergence of traditionally used foods as today’s probioticslong journey
Nishant et al. Bacteriocin producing probiotic lactic acid bacteria
Gagnon et al. Ecology of probiotics and enteric protection
Amer et al. Probiotics and Their Use in Inflammatory Bowel Disease.
Van Zyl Gastrointestinal persistence of the probiotic bacteria Lactobacillus plantarum 423 and Enterococcus mundtii ST4SA, and their anti-listerial activity
US20200268017A1 (en) Probiotic compositions and methods
Li Modification and development of probiotic strains Saccharomyces boulardii CNCM I-745 and Lacticaseibacillus rhamnosus GG

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160311

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170501